Yuji Ishida1,2, Tje Lin Chung3,4, Michio Imamura2, Nobuhiko Hiraga2, Suranjana Sen3, Hiroshi Yokomichi1, Chise Tateno1,2, Laetitia Canini3,5, Alan S Perelson6, Susan L Uprichard3, Harel Dahari3, Kazuaki Chayama2. 1. PhoenixBio Co., Ltd., Hiroshima, Japan. 2. Liver Research Project Center, Hiroshima University, Hiroshima, Japan. 3. The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL. 4. Institute of Biostatistics and Mathematical Modeling, Department of Medicine, Goethe University, Frankfurt, Germany. 5. Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom. 6. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM.
Abstract
Chimeric urokinase type plasminogen activator (uPA)/severely severe combined immunodeficiency (SCID) mice reconstituted with humanized livers are useful for studying hepatitis B virus (HBV) infection in the absence of an adaptive immune response. However, the detailed characterization of HBV infection kinetics necessary to enable in-depth mechanistic studies in this in vivo HBV infection model is lacking. To characterize HBV kinetics post-inoculation (p.i.) to steady state, 42 mice were inoculated with HBV. Serum HBV DNA was frequently measured from 1 minute to 63 days p.i. Total intrahepatic HBV DNA, HBV covalently closed circular DNA (cccDNA), and HBV RNA was measured in a subset of mice at 2, 4, 6, 10, and 13 weeks p.i. HBV half-life (t1/2 ) was estimated using a linear mixed-effects model. During the first 6 hours p.i., serum HBV declined in repopulated uPA/SCID mice with a t1/2 = 62 minutes (95% confidence interval [CI] = 59-67). Thereafter, viral decline slowed followed by a 2-day lower plateau. Subsequent viral amplification was multiphasic with an initial mean doubling time of t2 = 8 ± 3 hours followed by an interim plateau before prolonged amplification (t2 = 2 ± 0.5 days) to a final HBV steady state of 9.3 ± 0.3 log copies (cps)/mL. Serum HBV and intrahepatic HBV DNA were positively correlated (R2 = 0.98). CONCLUSION: HBV infection in uPA/SCID chimeric mice is highly dynamic despite the absence of an adaptive immune response. Serum HBV t1/2 in humanized uPA/SCID mice was estimated to be ∼1 hour regardless of inoculum size. The HBV acute infection kinetics presented here is an important step in characterizing this experimental model system so that it can be effectively used to elucidate the dynamics of the HBV life cycle and thus possibly reveal effective antiviral drug targets. (Hepatology 2018).
Chimeric urokinase type plasminogen activator (uPA)/severely severe combined immunodeficiency (SCID) mice reconstituted with humanized livers are useful for studying hepatitis B virus (HBV) infection in the absence of an adaptive immune response. However, the detailed characterization of HBV infection kinetics necessary to enable in-depth mechanistic studies in this in vivo HBV infection model is lacking. To characterize HBV kinetics post-inoculation (p.i.) to steady state, 42 mice were inoculated with HBV. Serum HBV DNA was frequently measured from 1 minute to 63 days p.i. Total intrahepatic HBV DNA, HBV covalently closed circular DNA (cccDNA), and HBV RNA was measured in a subset of mice at 2, 4, 6, 10, and 13 weeks p.i. HBV half-life (t1/2 ) was estimated using a linear mixed-effects model. During the first 6 hours p.i., serum HBV declined in repopulated uPA/SCIDmice with a t1/2 = 62 minutes (95% confidence interval [CI] = 59-67). Thereafter, viral decline slowed followed by a 2-day lower plateau. Subsequent viral amplification was multiphasic with an initial mean doubling time of t2 = 8 ± 3 hours followed by an interim plateau before prolonged amplification (t2 = 2 ± 0.5 days) to a final HBV steady state of 9.3 ± 0.3 log copies (cps)/mL. Serum HBV and intrahepatic HBV DNA were positively correlated (R2 = 0.98). CONCLUSION:HBV infection in uPA/SCID chimeric mice is highly dynamic despite the absence of an adaptive immune response. Serum HBV t1/2 in humanized uPA/SCIDmice was estimated to be ∼1 hour regardless of inoculum size. The HBV acute infection kinetics presented here is an important step in characterizing this experimental model system so that it can be effectively used to elucidate the dynamics of the HBV life cycle and thus possibly reveal effective antiviral drug targets. (Hepatology 2018).
Authors: Marian E Major; Harel Dahari; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Avidan U Neumann; Stephen M Feinstone Journal: Hepatology Date: 2004-06 Impact factor: 17.425
Authors: A Abe; K Inoue; T Tanaka; J Kato; N Kajiyama; R Kawaguchi; S Tanaka; M Yoshiba; M Kohara Journal: J Clin Microbiol Date: 1999-09 Impact factor: 5.948
Authors: S A Whalley; J M Murray; D Brown; G J Webster; V C Emery; G M Dusheiko; A S Perelson Journal: J Exp Med Date: 2001-04-02 Impact factor: 14.307
Authors: Dara L Burdette; Scott Lazerwith; Jenny Yang; Henry L Y Chan; William E Delaney Iv; Simon P Fletcher; Tomas Cihlar; Becket Feierbach Journal: PLoS One Date: 2022-04-01 Impact factor: 3.240
Authors: Anastasia Hyrina; Dara Burdette; Zhijuan Song; Ricardo Ramirez; Ayse Okesli-Armlovich; Archana Vijayakumar; Jamie Bates; James L Trevaskis; Simon P Fletcher; William A Lee; Meghan M Holdorf Journal: PLoS One Date: 2022-08-04 Impact factor: 3.752